These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27232229)

  • 41. The action of MBL-associated serine protease 1 (MASP1) on factor XIII and fibrinogen.
    Krarup A; Gulla KC; Gál P; Hajela K; Sim RB
    Biochim Biophys Acta; 2008 Sep; 1784(9):1294-300. PubMed ID: 18456010
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Studies on the physiological changes of blood coagulation factor XIII during pregnancy and their significance (author's transl)].
    Hayano Y; Imai N; Karasawa T
    Nihon Sanka Fujinka Gakkai Zasshi; 1982 Apr; 34(4):469-77. PubMed ID: 7069252
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Modern methods of diagnosing blood hypercoagulability].
    Buchbarova V
    Khirurgiia (Sofiia); 1977; 30(1):79-84. PubMed ID: 327144
    [No Abstract]   [Full Text] [Related]  

  • 44. [Fibrinase: its role in hemostasis].
    Baluda VP
    Lab Delo; 1968; 6():355-9. PubMed ID: 4184650
    [No Abstract]   [Full Text] [Related]  

  • 45. Surgical care of patients with hereditary disorders of blood coagulation.
    Shulman NR
    Mod Treat; 1968 Jan; 5(1):61-83. PubMed ID: 4870180
    [No Abstract]   [Full Text] [Related]  

  • 46. [Thrombocyte proteins].
    Baluda VP; Shiriaev VV
    Usp Sovrem Biol; 1974; 78(3):371-84. PubMed ID: 4280851
    [No Abstract]   [Full Text] [Related]  

  • 47. [Pseudofibrinolysis in the thrombelastogram, factor XIII and fibrinogen split products in the 2nd half of normal pregnancy, during labor, and puerperium (author's transl)].
    Riedel H; Barthels M; Trobisch H
    Z Geburtshilfe Perinatol; 1973 Oct; 177(5):339-49. PubMed ID: 4777491
    [No Abstract]   [Full Text] [Related]  

  • 48. New approaches to old problems in the clotting of fibrinogen.
    Lorand L
    Ann N Y Acad Sci; 1983 Jun; 408():226-32. PubMed ID: 6575686
    [No Abstract]   [Full Text] [Related]  

  • 49. Therapeutic materials used in the treatment of coagulation defects.
    Smith JK; Bidwell E
    Clin Haematol; 1979 Feb; 8(1):183-206. PubMed ID: 367662
    [No Abstract]   [Full Text] [Related]  

  • 50. Regulation of factor XIIIa generation by fibrinogen.
    Curtis CG; Janus TJ; Credo RB; Lorand L
    Ann N Y Acad Sci; 1983 Jun; 408():567-76. PubMed ID: 6135381
    [No Abstract]   [Full Text] [Related]  

  • 51. [Diagnostics and therapy of hemolytic-hemorrhagic transfusion incidents].
    Brüster H
    Zentralbl Neurochir; 1972; 33(1):63-8. PubMed ID: 5072151
    [No Abstract]   [Full Text] [Related]  

  • 52. Human fibrinogen and asialo-fibrinogen: a comparison of coagulation parameters.
    Gentry PA; Alexander B
    Arch Biochem Biophys; 1976 Mar; 173(1):50-7. PubMed ID: 176955
    [No Abstract]   [Full Text] [Related]  

  • 53. Fibrinogen and factor XIII at the intersection of coagulation, fibrinolysis and inflammation.
    Hoppe B
    Thromb Haemost; 2014 Oct; 112(4):649-58. PubMed ID: 25182841
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Hemostasis in pulmonary allografts in dogs].
    Milhiet H; Andreassian B; Coquillaud JP; Barge J; Sotty M
    J Chir (Paris); 1971 Oct; 102(4):369-78. PubMed ID: 4400538
    [No Abstract]   [Full Text] [Related]  

  • 55. Factor XIII: novel structural and functional aspects.
    Komáromi I; Bagoly Z; Muszbek L
    J Thromb Haemost; 2011 Jan; 9(1):9-20. PubMed ID: 20880254
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Disorders of the blood and cerebrospinal fluid coagulation and anticoagulation systems in experimental brain injury].
    Iurchenko VP
    Biull Eksp Biol Med; 1971 Oct; 72(10):30-2. PubMed ID: 5126147
    [No Abstract]   [Full Text] [Related]  

  • 57. [Clotting analysis in a surgical clinic].
    Heinrichs C
    Zentralbl Chir; 1980; 105(8):481-94. PubMed ID: 7415653
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Statistic considerations in the treatment of patients with coagulation disorders: 2 methods of approach].
    Moro GF; Campolongo F
    Riv Ital Stomatol; 1983; 52(7-8):589-92. PubMed ID: 6236541
    [No Abstract]   [Full Text] [Related]  

  • 59. Colloids decrease clot propagation and strength: role of factor XIII-fibrin polymer and thrombin-fibrinogen interactions.
    Nielsen VG
    Acta Anaesthesiol Scand; 2005 Sep; 49(8):1163-71. PubMed ID: 16095459
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A review of the basic mechanisms of fibrinogen to fibrin conversion and of fibrinolysis: intravascular coagulation versus primary fibrinolysis.
    Colick JA; Fisher LM
    Va Med Mon (1918); 1970 May; 97(5):310-4 passimass. PubMed ID: 4276992
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.